ClinicalTrials.gg
Not yet recruitingNCT07654075Updated Jun 17, 2026

Transcutaneous Electrical Acupoint Stimulation for Perioperative Sleep Disturbances in Cancer Patients

An interventional study of transcutaneous electrical acupoint stimulation,TEAS and Sham Transcutaneous Electrical Acupoint Stimulation (Sham TEAS) in Postoperative Sleep Disturbance, sponsored by Second Hospital of Shanxi Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Second Hospital of Shanxi Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Postoperative sleep disturbance (POSD) is highly prevalent among cancer patients after tumor resection, affecting 43%-80% of perioperative individuals. Poor sleep aggravates postoperative pain, anxiety and adverse cardiovascular events, hindering postoperative recovery. Conventional hypnotic medicines carry potential risks of drug dependence and respiratory depression.

Transcutaneous Electrical Acupoint Stimulation (TEAS) is a non-invasive physical therapy derived from traditional acupuncture, which delivers low-frequency electrical stimulation on acupoints. Previous small-scale researches suggest TEAS may improve perioperative sleep, but high-quality randomized controlled trial evidence for cancer surgical patients is insufficient.

This single-center randomized sham-controlled trial aims to verify whether perioperative TEAS at Shenmen (HT7), Neiguan (PC6) and Hegu (LI4) can improve postoperative sleep quality, relieve surgical pain and regulate stress hormone level. A total of 176 eligible patients aged 18-75 years undergoing elective gastrointestinal or gynecologic cancer resection under general anesthesia will be enrolled and randomly divided into 1:1 intervention group and sham control group. The TEAS group receives acupoint electrical stimulation from pre-anesthesia to the end of surgery, while control group uses identical electrodes without actual electrical output. All subjects receive standardized anesthesia and routine postoperative analgesia. Researchers evaluate primary outcomes including PSQI and AIS sleep scales, alongside secondary indicators such as VAS pain score, QoR-15 and serum cortisol at postoperative Day1, Day3, Day7 and postoperative 30-day follow-up.

Read the detailed description
  1. Study Design Detail

    This is a single-center, prospective, randomized, parallel-group, sham-controlled clinical trial with 1:1 allocation ratio. Randomization will be implemented via sealed opaque envelope method; allocation concealment is strictly performed to avoid selection bias. Blinding settings: patients, outcome assessors and statistical analysts are blinded to group assignment, while operators delivering TEAS cannot be blinded due to operational characteristics. The total planned sample size is 176 subjects, with 88 participants in TEAS intervention group and another 88 in sham control group respectively.

  2. Full Inclusion \& Exclusion Criteria

    Inclusion criteria:

    1. Aged between 18-75 years old, ASA physical status grade I-III;
    2. Scheduled for elective open or laparoscopic gastrointestinal/gynecologic malignant tumor resection under general anesthesia;
    3. Preoperative Pittsburgh Sleep Quality Index (PSQI) ≥7 points;
    4. Voluntarily sign written informed consent and agree to complete all scheduled follow-up visits.

    Exclusion criteria:

    1. Pre-existing primary sleep apnea, severe insomnia or diagnosed mental sleep disorder;
    2. Skin lesion, allergy or scar on Shenmen (HT7), Neiguan (PC6), Hegu (LI4) acupoints that cannot paste stimulation electrodes;
    3. Long-term regular use of sedative-hypnotic drugs or antidepressants within 3 months before surgery;
    4. Severe hepatic, renal, cardiac or hematological system dysfunction;
    5. Pregnant or lactating female patients.
  3. Specific Intervention Protocol

    Intervention group: TEAS equipment outputs alternating dense-sparse wave (2Hz/10Hz), electrode pads are fixed bilaterally on Shenmen, Neiguan and Hegu acupoints. Stimulation starts 10 minutes before anesthesia induction and continues uninterruptedly until surgical closure and completion of anesthesia induction; stimulation intensity is adjusted to individual maximum tolerable numbness without obvious pain.

    Sham control group: identical electrode placement at same acupoints with same fixing method, but the stimulator keeps zero output current without any electrical stimulation; the duration of electrode wearing is consistent with intervention group.

    All enrolled patients receive standardized general anesthesia scheme formulated by department anesthesiologists, as well as unified postoperative intravenous patient-controlled analgesia (PCA) protocol without extra sleep-related drug intervention during trial period.

  4. Outcome Assessment Timing \& Test Specification

    All indicators will be assessed at four fixed time points: postoperative day 1 (POD1), postoperative day3 (POD3), postoperative day7 (POD7), postoperative 30-day outpatient follow-up.

    • Primary outcomes: PSQI and Athens Insomnia Scale (AIS) filled by patients under unified guidance to quantify sleep quality;
    • Secondary outcomes: ① QoR-15 scale for global postoperative recovery assessment; ② resting VAS pain score (0-10 scale); ③ total cumulative PCA analgesic consumption within postoperative 7 days; ④ peripheral venous blood sampling for serum cortisol laboratory testing, samples are preserved at -80℃ uniformly and tested by same laboratory detection kit.
  5. Statistical Plan

All collected data will be imported into SPSS 26.0 for statistical analysis. Measurement data conforming to normal distribution is expressed as mean±standard deviation and compared via t-test; non-normal data adopts median (interquartile range) with rank-sum test; enumeration data uses chi-square test. P\<0.05 is defined as statistically significant difference. Missing data will be processed via intention-to-treat (ITT) analysis principle.

02

Conditions studied

  • Postoperative Sleep Disturbance

Keywords

  • postoperative sleep disturbance
  • transcutaneous electrical acupoint stimulation
  • cortisol
  • Shenmen (HT7), Neiguan (PC6), Hegu (LI4)
03

In context

Lead sponsor

Second Hospital of Shanxi Medical University is the lead sponsor of 28 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 75 years old, regardless of gender.
  • Diagnosed with malignant tumors requiring elective surgery under general anesthesia.
  • I-III.
  • Able to understand and complete study-related questionnaires (PSQI, AIS, NRS, etc.).
  • Voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac, hepatic, renal or respiratory dysfunction that affects the implementation of TEAS.
  • History of psychiatric disorders or use of psychotropic drugs.
  • History of drug or alcohol abuse.
  • Presence of infection, skin lesions or at TEAS acupoints.
  • Preoperative use of strong opioids (e.g., morphine, oxycodone) for more than 1 week.
  • Pregnant or lactating women.
  • Participation in other clinical trials within 3 months prior to enrollment.
  • Inability to cooperate with the study due to cognitive impairment or language barriers.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    TEAS Intervention Group

    Patients receive perioperative TEAS plus standard analgesia

    Device: transcutaneous electrical acupoint stimulation,TEAS

  • Sham comparator
    Sham TEAS Control Group

    Patients receive sham TEAS plus standard analgesia

    Device: Sham Transcutaneous Electrical Acupoint Stimulation (Sham TEAS)

Interventions

  • Devicetranscutaneous electrical acupoint stimulation,TEAS

    TEAS will be applied to LI4, PC6 HT7 and for 30mins preoperatively and continued postoperatively

  • DeviceSham Transcutaneous Electrical Acupoint Stimulation (Sham TEAS)

    Sham TEAS with identical electrode placement but no electrical stimulation, combined with standard postoperative analgesia.

06

What researchers measure

Primary outcomes

  1. Evaluation of postoperative sleep quality

    Athens Insomnia Scale (AIS), an 8-item self-reported questionnaire evaluating insomnia severity over the past month. Each item is rated from 0 (no problem) to 3 (severe problem). The total score ranges from 0 to 24, with higher scores indicating greater insomnia severity and poorer sleep quality. A score of ≥6 is commonly used as the cutoff for clinically significant insomnia.

    Time frame: postoperative day 1,postoperative day 3,postoperative day 7,and postoperative day 30

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jul 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 17, 2026
StartEst.
Jun 13, 2026
Primary completionEst.
Jul 12, 2026
CompletionEst.
Jul 20, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07654075
Lead sponsor
Second Hospital of Shanxi Medical University
Responsible party
Zheng Guo (Professor, Second Hospital of Shanxi Medical University) — Principal investigator
First posted
Jun 17, 2026
Start date
Jun 13, 2026 (estimated)
Primary completion
Jul 12, 2026 (estimated)
Completion
Jul 20, 2026 (estimated)
Last update
Jun 17, 2026

Study contacts

Ting Wang
Contact
1148460358@qq.com
+86 18331359550
Ying Xiao Zhao
study director · Second Hospital of Shanxi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion